Recent Updates — AEMD

Aethlon Medical stockholders approved an amendment to the Articles of Incorporation at the October 1, 2026 annual meeting to increase the number of authorized common shares from 20 million to 200 million. The amendment was filed with the Secretary of State of Nevada and became effective on October 7, 2026. Aethlon Medical develops medical devices for blood purification.

Aethlon Medical, Inc.'s stockholders failed to approve Proposal No. 7 at the 2026 Annual Meeting, which sought to amend the Articles of Incorporation to authorize 20,000,000 additional shares of preferred stock. The proposal required a majority of outstanding common shares for approval but received only 204,122 votes in favor against 9,529 opposed and 184,547 broker non-votes. Consequently, the company's charter remains unchanged regarding preferred equity authorization. Aethlon Medical operates in the medical device industry, specializing in blood purification technologies.

Aethlon Medical, Inc. entered into a definitive merger agreement with North Immunology, Inc., an all-stock transaction where North Immunology will become a wholly owned subsidiary before merging into Aethlon's surviving entity. The combined company will operate as North Immunology, Inc., trading on Nasdaq under the ticker NRTX, with pre-merger North Immunology stockholders expected to own approximately 95.25% of the new entity and Aethlon shareholders retaining about 4.75%. Concurrently, a $180 million oversubscribed private placement (PIPE) is closing immediately prior to the merger, consisting of $146 million in cash and $34 million from convertible notes, providing capital through the second half of 2028. Aethlon shareholders will receive one contingent value right per share, entitling them to proceeds from any future monetization of Aethlon's legacy Hemopurifier assets. The transaction is expected to close in Q1 2027, subject to stockholder and regulatory approvals. Aethlon Medical operates as a medical therapeutic company developing immunotherapeutic devices for cancer and viral diseases.